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Objective: To investigate clinically severe malaria patients with Plasmodium falciparum
(P. falciparum), Plasmodium vivax (P. vivax) and mixed species infections.
Methods: This study was conducted at Dr. Saiful Anwar General Hospital, Malang,
Indonesia, from December 2011 to May 2013. Twenty nine patients (mean age of 41
years, 22% female), who suffered from severe malaria according to World Health Or-
ganization criteria (major and minor) and other criteria based on previous studies, were
selected by consecutive sampling. Blood samples were obtained at admission from pe-
ripheral blood for microscopic diagnostic, nested PCR and laboratory examination of
blood chemistry. Laboratory results were compared between the groups and correlated to
each other.
Results: From 29 samples, eight (28%) were diagnosed as P. falciparum mono-infection,
12 (41%) as P. vivax mono-infection and nine (31%) as mixed infections, conﬁrmed by
PCR. Cerebral malaria occurred in P. falciparum or mixed species infection only. Para-
sitaemia was highest in P. falciparum mono-infection. Mean haemoglobin was signiﬁ-
cantly lower in P. falciparum than P. vivax infection (P = 0.01). Mean thrombocyte count
(77138/mL) was low in all groups. Mean urea, creatinine, total and direct bilirubin were
signiﬁcantly higher in P. falciparum mono-infection compared to other groups, whereas
aspartate aminotransferase and alanine aminotransferase showed no signiﬁcant differ-
ences. Parasitaemia was positively correlated with an increase in urea, creatinine, bilirubin
and leucocytosis in all species.
Conclusions: Both Plasmodium species can solely or in combination cause severe ma-
laria. Mixed infection was generally more benign than P. falciparum mono-infection and
seemed to have some protective effects.1. Introduction
Malaria, as an infectious disease, remains a major health
problem in the world, especially in tropical and developing
countries. In Indonesia, malaria is one of the top ten infectious
diseases with an incidence of 1.9% and a prevalence of 6.0% in
2013 [1]. The World Health Organization estimated that about
198 million people worldwide suffered from malaria with a
mortality rate of approximately 584000 cases in 2013 [2].article under the CC BY-NC-ND license (http://
Table 1
Criteria of severe malaria.
Clinical criteria Parameter value
Impaired consciousness Glasgow coma scale < 15
Prostration (+)








Circulatory collapse or shock Systolic blood pressure < 80 mmHg
in adults and < 50 mmHg in
children
Abnormal bleeding (+)
Acute kidney injury Creatinine > 2.5 mg/dL or
< 400 mL/24 h)
Clinical jaundice plus
evidence of
other vital organ dysfunction
Bilirubin > 3 mg/dL;
ALT/AST > 3 times elevated
Metabolic acidosis Plasma bicarbonate < 15 mmol/L,
pH < 7.25
Severe normocytic anaemia Haemoglobin < 5 g/dL, packed cell
volume < 15% in children; < 7 g/dL,
packed cell volume < 20% in adults
Haemoglobinuria (+)
Hyperlactatemia Lactate > 5 mmol/L
Hypoglycaemia < 2.2 mmol/L or < 40 mg/dL
Pulmonary oedema (+) Radiological




AST > 38 IU/L in male; > 32 IU/L in
female
ALT > 41 IU/L in male; > 31 IU/L in
female
Creatinine > 1.4 mg/dL in male; > 1.1 mg/dL in
female
Urea > 50 mmol/L
Jaundice Serum bilirubin > 50 mmol/L or
> 3 mg/dL
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transmitted by Anopheles sp. mosquito as vector. There are ﬁve
human-pathogenic species of Plasmodium known: Plasmodium
vivax (P. vivax), Plasmodium falciparum (P. falciparum),
Plasmodium ovale (P. ovale) (P. ovale wallikeri and P. ovale
curtesi), Plasmodium malariae (P. malariae) and Plasmodium
knowlesi (P. knowlesi) [3,4]. Each species has different clinical
symptoms. P. falciparum is known to cause the most se-
vere clinical symptoms with cerebral malaria as a major
complication. However, some recent researches suggested that
other Plasmodium such as P. vivax and P. knowlesi were also
responsible for severe manifestations. P. vivax can cause
severe clinical outcome because of the simultaneous increase
of the tumour necrosis factor, interferon-g and interleukin-10
[5]. In a case series of severe vivax malaria conducted by
O'Brien et al., jaundice and severe thrombocytopaenia were
the major complications [6].
Parasite density may affect the severity of clinical symptoms
of malaria and the laboratory results. Based on a study con-
ducted by Tangpukdee et al., high parasite density was associ-
ated with severe clinical illness, complications and mortality [7].
Further investigation of the relationship between parasite
density and elevation of laboratory blood chemistry parameters
in severe malaria infection could help to reveal differences
and common features in P. falciparum and P. vivax infections.
Therefore, this study on parasite density and blood chemistry
parameters such as urea, creatinine, bilirubin (direct, indirect,
and total), aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) in severe P. falciparum and P. vivax patients
was conducted.
2. Materials and methods
The study was conducted from December 2011 to May 2013
at Dr. Saiful Anwar General Hospital, Malang, Laboratory of
Parasitology and Biomedical Central Laboratory, Faculty of
Medicine, University of Brawijaya, Indonesia. The area is not
endemic for malaria. Severely ill patients are referred to the
University Hospital from rural areas of Java and other nearby
islands. A total of 29 severe malaria patients (positive malaria
parasite slide or rapid diagnostic test (RDT) later-conﬁrmed by
nested PCR) were selected through consecutive sampling tech-
nique after written informed consent. Each patient showed at
least one sign or symptom of severe malaria according to World
Health Organization criteria and other criteria that had been
reported previously for severe or complicated P. vivax [8–10].
Severity criteria of samples are shown in Table 1. Blood sam-
ples were taken from patients at admission. Patients had been ill
for 3–14 days before admission. Patient follow-ups were done
by a doctor in charge, but data were not included in this research.
Diagnosis of malaria was based on thick and thin blood ﬁlm and/
or RDT and later-conﬁrmed by nested PCR. Detailed history
was taken and complete physical examination was performed.
Patients were treated based on guidelines from Ministry of
Health of Indonesia. Severe malaria patients were treated with
artesunate injection, while uncomplicated malaria patients were
treated with oral dihydroartemisinin + piperaquine [11].
Five millilitres peripheral venous blood (medial cubital vein)
from each patient were collected in an ethylene diamine tetra-
acetic acid vacutainer. Blood samples were processed for thick
and thin blood smears for microscopic examination, nested PCR
to conﬁrm the diagnosis, and laboratory examination of bloodchemistry. Thick and thin blood smears were prepared according
to standard procedures. Slides were stained with 10% Giemsa
for 30 min and independently read by two experienced parasi-
tologists. Asexual parasites were counted on thin blood ﬁlms
among 1000 red blood cells to attain percentage of parasitized
red blood cells. Slides were declared negative if no parasites
were seen in 200 ﬁelds of the thick ﬁlm.
Chemical laboratory values were measured at the central
laboratory of Dr. Saiful Anwar General Hospital using automatic
blood cell counter and automatic analyser laboratory unit.
Normal values were blood urea  50 mmol/L; creatinine
 1.4 mg/dL in men,  1.1 mg/dL in women; AST  38 IU/L in
men,  32 IU/L in women; ALT  41 IU/L in men,  31 IU/L
in women; total bilirubin < 1.1 mg/dL; direct bilirubin
 0.125 mg/dL; indirect bilirubin  0.8 mg/dL.
DNA isolation was performed using PureLink™ Genomic
DNA Kits (Invitrogen®), nested PCR was performed using 2×
PCR Master Mix (Norgen®), and primers for genus and species
identiﬁcation of Plasmodium was used as described previously
[12] after optimization.
The mean, minimum and maximum of parasite density and
laboratory alterations were calculated. Proportions were calcu-
lated and analysed by Chi-squared test. Means were compared
by student's t-test and Mann–Whitney–Wilcoxon test if
Bagus Hermansyah et al./Asian Pac J Trop Biomed 2017; 7(1): 4–96appropriate. Correlations between parasite density and labora-
tory parameters were analysed using logistic regression models.
A signiﬁcance level of P < 0.05 was chosen. The statistical
program used was Stata version 11.0 (StataCorp, Texas, USA).
Ethical approval was obtained from the Ethical Committee
Medical Research of Faculty of Medicine, University of
Brawijaya.
3. Results
Thirty ﬁve malaria patients were admitted at Dr. Saiful
Anwar General Hospital during the study and six patients were
excluded due to clinically uncomplicated cases, so 29 subjects
with severe malaria were enrolled in this study. Six (20.7%)
patients were females. Microscopy showed 18 P. falciparum
mono-infections, 10 P. vivax mono-infections and one mixed
species infection. Molecular diagnosis by PCR conﬁrmed eight
P. falciparum mono-infections (Group 1) and 12 P. vivax in-
fections (Group 2), whereas the remainder (nine) were mixed
species infections (Group 3). None of the subjects was infected
with P. malariae, P. ovale or P. knowlesi. Baseline, clinical and
laboratory data are shown in Table 2.
The degree of parasitaemia varied between 0.01% and
6.90%. There was one microscopically negative sample that wasTable 2
Baseline, clinical and laboratory data from all species.
Data All P. falcipar
Species (by PCR) [n (%)] N = 29 8 (27.
Species (by microscopy) [n (%)] 18 (62.
Gender [n (%)]
Male 23 (79.3) 6 (75.
Female 6 (20.7) 2 (25.
Mean age in years (SD; range) 41.4 (12.3; 22.0–69.0) 40.6 (10.
Parasitaemia (%) (SD; range) 1.47 (1.75; 0.01–6.90)a 3.04 (2.3
Cerebral malaria [n (%)]
No 22 (75.9) 3 (37.
Yes 7 (24.1)c 5 (62.
Seizure [n (%)]
No 27 (93.1) 7 (87.
Yes 2 (6.9) 1 (12.
Mean haemoglobin
(mg/dL) (SD; range)
















63 (65; 19–278) 124 (97;
Mean creatinine
(mg/dL) (SD; range)
1.5 (2.0; 0.6–9.6) 2.8 (3.5
Mean AST (IU/L)
(SD; range)
76 (67; 19–356) 79 (31;
Mean ALT (IU/L)
(SD; range)
57 (30; 13–124) 48 (26;
N = 25
Mean total
bilirubin (mg/dL) (SD; range)
4.3 (7.5; 0.2–24.2) 10.1 (12.
Mean direct
bilirubin (mg/dL) (SD; range)
2.9 (5.9; 0.0–26.9) 7.6 (9.9
Mean indirect
bilirubin (mg/dL) (SD; range)
1.4 (1.7; 0.2–7.2) 2.5 (2.8
a: P < 0.05 by student's t-test compared with mean parasitaemia of P. falcipa
regression shows P < 0.05 between marked groups; c: P < 0.05 by Chi-squpositively tested for P. falciparum by RDT and conﬁrmed by
PCR. Mean parasitaemia in P. falciparum malaria was 3.04%
compared to 0.35% and 1.58% in P. vivax and mixed species
infection, respectively. Patients with P. falciparum malaria
(Group 1) presented with a signiﬁcantly higher parasitaemia than
patients in Group 2 (P  0.01) or Group 3 (P  0.04) in logistic
regression models controlled for gender and age. A student's t-
test showed similar results (P < 0.01 when P. falciparum
compared to P. vivax, P < 0.01 when P. vivax compared to
mixed species, P = 0.13 when P. falciparum compared to mixed
species).
Cerebral malaria and seizures only occurred in P. falciparum
mono-infection and mixed species infection. Results showed
that 62.5% of Group 1 and 22.2% of Group 3 showed cerebral
symptoms.
Mean haemoglobin was signiﬁcantly lower in P. falciparum
than that in P. vivax infection (P = 0.02, controlled for gender
P = 0.01). Haemoglobin in Group 3 was higher than that in
Group 1 but the difference was not signiﬁcant. Females had in
general lower haemoglobin (8.7 mg/dL, SD = 1.8) than males
(10.8 mg/dL, SD = 2.7, P = 0.08).
Mean leucocyte count was signiﬁcantly higher in P. falciparum
than P. vivax infection (P = 0.06, controlled for gender P = 0.04).
Leucocytes were ranging between 2380 and 23500/mL in Groupum (Group 1) P. vivax (Group 2) Mixed species (Group 3)
6) 12 (41.4) 9 (31.0)
1) 10 (34.5) 1 (3.4)
0) 8 (66.7) 9 (100.0)
0) 4 (33.3) 0 (0.0)
5; 22.0–60.0) 39.4 (10.2; 26.0–59.0) 41.6 (14.2; 22–69)
8; 0.21–6.90)b 0.35 (0.18; 0.01–0.60)b 1.58 (1.20; 0.10–3.50)b
5) 12 (100.0) 7 (77.8)
5) 0 (0.0) 2 (22.2)
5) 12 (100.0) 8 (88.9)
5) 0 (0.0) 1 (11.1)












39–278)b 30 (17; 19–78)b 47 (16; 26–77)b
; 0.7–9.6)b 0.9 (0.3; 0.6–1.5)b 1.1 (0.2; 0.9–1.5)b
40–121) 84 (96; 23–356) 64 (38; 19–116)
13–83) 68 (33; 18–124) 49 (27; 22–98)
7 9 9
7; 1.5–34.2)b 2.1 (2.3; 0.2–6.9)b 2.0 (2.0; 0.3–6.6)b
; 0.5–26.9)b 1.1 (1.4; 0.0–3.5)b 1.2 (1.3; 0.2–4.0)b
; 0.3–7.2) 1.0 (1.0; 0.2–3.4) 0.9 (0.7; 0.2–2.5)
rum and P. vivax as well as of P. vivax and mixed infection; b: Logistic
ared test compared with all groups.
Table 3
Leucocyte differentiation and ML-ratio by species.
Parameter All (n = 19) P. vivax (n = 10) Mixed (n = 9)
Mean absolute lymphocytes (SD; range) 1338 (875; 125–2886) 1175 (952; 125–2886) 1627 (748; 628–2538)
Mean absolute monocytes (SD; range) 457 (406; 48–1518) 356 (256; 122–954) 655 (490; 149–1518)
ML-ratio (SD) 0.414 (0.286) 0.413 (0.279) 0.449 (0.308)
NLCR (SD) 4.52 (4.03) 5.53 (5.13) 3.51 (2.44)
Mean relative eosinophiles (SD; range) 1.6 (2.0; 0.0–9.0) 1.9 (2.6; 0.0–9.0) 1.5 (1.4; 0.0–4.0)
Mean relative basophiles (SD; range) 0.3 (0.6; 0.0–2.2) 0.4 (0.7; 0.0–2.2) 0.3 (0.4; 0.0–1.0)
Mean relative lymphocytes (SD; range) 22.3 (14.8; 1.0–56.0) 20.5 (16.4; 1.0–55.0) 25.0 (14.2; 11.0–56.0)
Mean relative monocytes (SD; range) 7.5 (5.3; 1.0–22.0) 6.0 (3.7.0; 1.0–11.0) 9.8 (6.3; 2.0–22.0)
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Groups 2 and 3. Lymphocytes were low in both groups, other
values were relatively normal and showed no differences between
the groups. The overall monocyte-lymphocyte-ratio (ML-ratio)
was 0.414. The neutrophil-lymphocyte count ratio (NLCR) was
4.52 on average. Group 2 showed a higher NLCR than Group 3
but the difference was not signiﬁcant (Table 3).
Thrombocytes were low in all groups ranging between
12000 and 207000. Groups 2 and 3 showed lower mean
trombocytaemia than Group 1 but the difference was not
signiﬁcant.
Mean urea (124 mmol/L) and mean creatinine (2.8 mg/dL)
were highly elevated in P. falciparum mono-infection and
signiﬁcantly higher than those in both other groups.
Total bilirubin (10.1 mg/mL) was highly elevated in Group 1
and only moderately elevated in the other groups (2.1 mg/mL in
Group 2 and 2.0 mg/mL in Group 3). Logistic regression
showed signiﬁcant differences between Group 1 and Group 2 as
well as Group 1 and Group 3 (controlled for gender P = 0.04
and 0.02, respectively). The same was observed for direct
bilirubin (7.6 mg/mL) between the groups (controlled for
gender P = 0.03 and 0.02, respectively), whereas indirect bili-
rubin was relatively normal and showed no signiﬁcant differ-
ences between the groups. AST and ALT showed only
moderately elevated levels in all patients, there was no differ-
ence observed.
Parasitaemia was positively correlated with an increase of
urea, creatinine, bilirubin and leucocytosis (Table 2). The corre-
lation was signiﬁcant for urea, creatinine and leucocytosis in all
patients (controlled for gender P  0.01, P  0.01 and P  0.01,
respectively). Further analysis of the different groups was difﬁ-
cult regarding the low sample size. Relationship between creati-
nine and parasitaemia was most pronounced in Group 1. Increase
in bilirubin (total, indirect and direct) was signiﬁcantly correlated
with parasitaemia in the mixed species group only.
On average, parasitaemia in females was higher than in males
but the overall difference was not signiﬁcant (P = 0.496).
However, the P. vivax group showed signiﬁcantly higher para-
sitaemia in females than in males (P = 0.043). Group 1 consisted
of 6 males and 2 females, Group 2 consisted of 8 males and 4
females, and Group 3 consisted of 9 males only.
4. Discussion
In this study, 29 severe malaria cases were recruited from
December 2011 to May 2013. Malaria was caused by P. vivax
(41.4%), by mixed infection of P. falciparum and P. vivax
(31.0%) and by P. falciparum alone (27.6%). Microscopy and
PCR correlated poorly, especially in mixed infections. If avail-
able, molecular conﬁrmation is therefore recommendable as itmight have important treatment consequences due to the
different regimens in P. falciparum and P. vivax malaria.
The high number of severe malaria cases caused by P. vivax
is an interesting phenomenon since this species rarely causes
severe malaria compared with P. falciparum. This result is
consistent with several reports that P. vivax is not as benign as
recently thought [5,13,14]. A change in the pattern of Plasmodium
species that cause severe malaria was observed at the Dr. Saiful
Anwar General Hospital Malang, Indonesia. Our previous study
reported two cases of severe P. vivax malaria from Malang,
Indonesia. Patients exhibited anaemia, thrombocytopaenia,
jaundice, renal disturbance, and melaena [15].
None of the patients was infected with P. malariae, P. ovale
or P. knowlesi infection. The reason might be the small sample
size, the rareness of those three species in Indonesia, especially
in Java Island, and their normally benign character [4,16].
No cerebral symptoms occurred in P. vivax mono-infection.
Although the paradigm that P. vivax is incapable of cyto-
adherence is questioned nowadays, the pathology seems to be
different to P. falciparum [17]. Also, the degree of mean
parasitaemia varied between the three groups and was highest
in P. falciparum mono-infection with 3.04% compared to
0.35% and 1.58% in P. vivax mono-infection and mixed
infection, respectively. Higher parasitaemia in P. falciparum is
expected as it attacks all erythrocytes but P. vivax only
invades reticulocytes. However, mixed infection showed
signiﬁcantly lower parasitaemia than P. falciparum mono-
infection (P < 0.01). A protective effect of P. vivax was dis-
cussed and observed in a recent study but mechanisms are un-
clear so far [18]. Relative P. vivax parasitaemia was higher and
haemoglobin in general was lower in females than in males,
the latter might be the explanation for the higher parasitaemia.
Mean haemoglobin was lowest in Group 1 and signiﬁcantly
higher in Group 2. Mixed infections showed higher mean hae-
moglobin than Group 1, but the difference was not signiﬁcant.
Anaemia correlates closely with parasitaemia due to destruction
of parasitized erythrocytes.
Bacterial infections and septicaemia are associated with both
malaria species as recent studies reported [19,20]. In this study,
leucocytosis in Group 1 was higher than that in Groups 2 or
3, the difference was distinct but not signiﬁcant (P = 0.08
or 0.18, respectively). Parasitaemia and leucocytosis were
positively correlated (P < 0.01) but blood culture was not
performed for conﬁrmation of bacterial infection. As described
before, mean thrombocythemia was generally low [21].
ML-ratio was introduced by Warimwe et al. as parameter for
the risk of clinical manifestation of malaria [22]. The ML-ratio in
severe malaria patients from Indonesia was high compared to
children with asymptomatic parasitaemia in Kenya. Acute ma-
laria infection probably increases the ML-ratio but no baseline
Bagus Hermansyah et al./Asian Pac J Trop Biomed 2017; 7(1): 4–98data before infection were available for comparison. There was
no difference between Groups 2 and 3.
The ratio of NLCR was proposed as a parameter of systemic
inﬂammation and stress. Wolfswinkel et al. found that the
NLCR correlated with parasitaemia in imported malaria patients
[23]. NLCR was highest in severe malaria falciparum compared
to uncomplicated falciparum and non-falciparum malaria but the
difference was not signiﬁcant. Mean NLCR was comparable in
Indonesian patients with no signiﬁcant difference between the
groups.
Increased level of blood urea (> 50 mmol/L) were found in
all but one patient with P. falciparum mono-infection, in only
one patient with P. vivax mono-infection and in 55.6% of Group
3. Urea concentration correlated positively with parasitaemia
(P < 0.001, R2 = 0.41).
Mean creatinine was signiﬁcantly higher in Group 1 than
Groups 2 or 3 (P = 0.01), correlation controlled for gender with
parasitaemia was highly positive as well (P = 0.001, R2 = 0.41).
Increased levels of blood urea and creatinine revealed that dis-
turbances of renal function in P. falciparum infection were more
frequent than in P. vivax infections in accordance with other
studies [24,25]. Plewes et al. reported that parasite density
was positively correlated (r = 0.49, P < 0.001) with serum
creatinine in P. falciparum infection [26], as observed in this
study. Malaria can cause disturbance of renal function through
mechanisms of mechanical obstruction by infected erythrocytes,
glomerular and tubular damage associated with immune
pathology, hypovolaemia due to various reasons and decreased
renal microcirculation [25]. Severe uraemia was found in one
P. falciparum patient (275.7 mmol/L) causing death due to
uraemic encephalopathy.
Liver enzymes were only slightly elevated in all groups,
highest in the P. vivax group but differences between the groups
were not signiﬁcant. The ﬁndings were in accordance with a
previous study by Pir et al. that demonstrated similar increased
ALT levels in P. falciparum and P. vivax infections [27]. Hepatic
dysfunction in malaria infection is common and varies from mild
to severe, it is often associated with the onset of complications and
mortality [28]. Increased AST and other inﬂammatory markers in
severe P. vivax infection were also reported by Chaves et al. [5].
Jaundice is a very common manifestation in malaria and
correlates usually with parasitaemia. Bilirubin levels and para-
sitaemia were positively correlated but the association was not
signiﬁcant (P = 0.15). Jaundice in malaria is the result of
intravascular haemolysis of infected erythrocytes, stress-induced
normal erythrocyte haemolysis and hepatic dysfunction [29]. All
patients with P. falciparum mono-infection had elevated total
and direct bilirubin, 55.6% each of Group 2 and Group 3 also
showed elevated values, the difference between Groups 1 and 2
as well as 1 and 3 was signiﬁcant by logistic regression models
controlled for gender and by Mann–Whitney test. This is
consistent with a study conducted by Pir et al. showing an in-
crease in bilirubin more often in P. falciparum than P. vivax
infection [27]. This ﬁts the ﬁnding that parasitaemia was
positively correlated with bilirubin levels.
Comparing Group 1 and Group 3, parasitaemia was signiﬁ-
cantly lower in Group 3 and cerebral symptoms, anaemia and
leucocytosis less often as well. Creatinine, urea and bilirubin
were signiﬁcantly lower in mixed infection than in P. falciparum
mono-infection. A protective effect of P. vivax seems to be the
only plausible explanation. More studies to elucidate these
ﬁndings and the mechanisms behind them should be conducted.Severe malaria caused by different species of Plasmodium
has some similarities and differences in terms of clinical features
and laboratory results. Both P. falciparum and P. vivax in-
fections can cause severe malaria although P. vivax mono-
infection presented without cerebral symptoms. Parasitaemia
was positively correlated with an increase in urea, creatinine,
bilirubin and leucocytosis.
Interestingly, mixed infections were overall more benign than
P. falciparum mono-infections with lower parasitaemia and less
cerebral symptoms. This could indicate a protective effect of
mixed infections compared to P. falciparum mono-infections.
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